Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011
- PMID: 23629712
- PMCID: PMC3697312
- DOI: 10.1128/AAC.00484-13
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011
Abstract
Vancomycin, linezolid, and daptomycin are very active against staphylococci, but isolates with decreased susceptibility to these antimicrobial agents are isolated sporadically. A total of 19,350 Staphylococcus aureus isolates (51% methicillin resistant [MRSA]) and 3,270 coagulase-negative staphylococci (CoNS) were collected consecutively from 82 U.S. medical centers from January 2008 to December 2011 and tested for susceptibility against ceftaroline and comparator agents by the reference broth microdilution method. Among S. aureus strains, 14 isolates (0.07%) exhibited decreased susceptibility to linezolid (MIC, ≥ 8 μg/ml), 18 (0.09%) to daptomycin (MIC, ≥ 2 μg/ml), and 369 (1.9%) to vancomycin (MIC, ≥ 2 μg/ml; 368 isolates at 2 μg/ml and 1 at 4 μg/ml). Fifty-one (1.6%) CoNS were linezolid resistant (MIC, ≥ 8 μg/ml), and four (0.12%) were daptomycin nonsusceptible (MIC, ≥ 2 μg/ml). Ceftaroline was very active against S. aureus overall (MIC50/90, 0.5/1 μg/ml; 98.5% susceptible), including MRSA (MIC50/90, 0.5/1 μg/ml; 97.2% susceptible). All daptomycin-nonsusceptible and 85.7% of linezolid-resistant S. aureus isolates were susceptible to ceftaroline. Against S. aureus isolates with a vancomycin MIC of ≥ 2 μg/ml, 91.9, 96.2, and 98.9% were susceptible to ceftaroline, daptomycin, and linezolid, respectively. CoNS strains were susceptible to ceftaroline (MIC50/90, 0.25/0.5 μg/ml; 99.1% inhibited at ≤ 1 μg/ml), including methicillin-resistant (MIC50/90, 0.25/0.5 μg/ml), linezolid-resistant (MIC50/90, 0.5/0.5 μg/ml), and daptomycin-nonsusceptible (4 isolates; MIC range, 0.03 to 0.12 μg/ml) strains. In conclusion, ceftaroline demonstrated potent in vitro activity against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin, and it may represent a valuable treatment option for infections caused by these multidrug-resistant staphylococci.
Similar articles
-
In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.J Glob Antimicrob Resist. 2018 Jun;13:221-225. doi: 10.1016/j.jgar.2018.01.022. Epub 2018 Feb 5. J Glob Antimicrob Resist. 2018. PMID: 29421316
-
Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.Antimicrob Agents Chemother. 2011 Sep;55(9):4154-60. doi: 10.1128/AAC.00315-11. Epub 2011 Jun 27. Antimicrob Agents Chemother. 2011. PMID: 21709080 Free PMC article.
-
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.Int J Antimicrob Agents. 2014 Apr;43(4):323-7. doi: 10.1016/j.ijantimicag.2013.11.005. Epub 2013 Dec 11. Int J Antimicrob Agents. 2014. PMID: 24411474
-
In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).Clin Infect Dis. 2012 Sep;55 Suppl 3:S206-14. doi: 10.1093/cid/cis563. Clin Infect Dis. 2012. PMID: 22903953 Review.
-
The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopristin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis.Antimicrob Resist Infect Control. 2020 Apr 22;9(1):56. doi: 10.1186/s13756-020-00714-9. Antimicrob Resist Infect Control. 2020. PMID: 32321574 Free PMC article.
Cited by
-
Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.Antimicrob Agents Chemother. 2014 Oct;58(10):5736-46. doi: 10.1128/AAC.03019-14. Epub 2014 Jul 14. Antimicrob Agents Chemother. 2014. PMID: 25022592 Free PMC article.
-
Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.Antimicrob Agents Chemother. 2015 Apr;59(4):1922-30. doi: 10.1128/AAC.04068-14. Epub 2015 Jan 12. Antimicrob Agents Chemother. 2015. PMID: 25583724 Free PMC article.
-
Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration.PLoS One. 2015 May 11;10(5):e0125818. doi: 10.1371/journal.pone.0125818. eCollection 2015. PLoS One. 2015. PMID: 25961578 Free PMC article.
-
In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.Antimicrob Agents Chemother. 2013 Nov;57(11):5600-11. doi: 10.1128/AAC.01485-13. Epub 2013 Aug 26. Antimicrob Agents Chemother. 2013. PMID: 23979759 Free PMC article.
-
Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.Antimicrob Agents Chemother. 2015 May;59(5):2583-7. doi: 10.1128/AAC.05119-14. Epub 2015 Feb 17. Antimicrob Agents Chemother. 2015. PMID: 25691627 Free PMC article.
References
-
- Boucher H, Miller LG, Razonable RR. 2010. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 51(Suppl 2):S183–S197 - PubMed
-
- Sader HS, Moet GJ, Farrell DJ, Jones RN. 2011. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Diagn. Microbiol. Infect. Dis. 70:412–416 - PubMed
-
- Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. 2011. Antimicrobial resistance: not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA—its evolving antimicrobial resistance and implications for therapy. Clin. Infect. Dis. 52:99–114 - PubMed
-
- Garau J, Bouza E, Chastre J, Gudiol F, Harbarth S. 2009. Management of methicillin-resistant Staphylococcus aureus infections. Clin. Microbiol. Infect. 15:125–136 - PubMed
-
- van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 54:755–771 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical